Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol

Journals

1. Hoornenborg E, Krakower D, Prins M, Mayer K. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS 2017;31(16):2179 View
2. Torres T, De Boni R, de Vasconcellos M, Luz P, Hoagland B, Moreira R, Veloso V, Grinsztejn B. Awareness of Prevention Strategies and Willingness to Use Preexposure Prophylaxis in Brazilian Men Who Have Sex With Men Using Apps for Sexual Encounters: Online Cross-Sectional Study. JMIR Public Health and Surveillance 2018;4(1):e11 View
3. Kenyon C. We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in preexposure prophylaxis cohorts. AIDS 2019;33(1):155 View
4. Reyniers T, Nöstlinger C, Vuylsteke B, De Baetselier I, Wouters K, Laga M. The Impact of PrEP on the Sex Lives of MSM at High Risk for HIV Infection: Results of a Belgian Cohort. AIDS and Behavior 2021;25(2):532 View
5. Kenyon C. Toward a Set of Criteria to Decide Which STIs to Screen for in PrEP Cohorts. Frontiers in Public Health 2019;7 View
6. Wu D, Tao H, Dai J, Liang H, Huang A, Zhong X. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study. International Journal of Environmental Research and Public Health 2019;16(24):4996 View
7. Vuylsteke B, Reyniers T, Lucet C, Nöstlinger C, Deblonde J, Libois A, Sauvage A, Deprez E, Goffard J, Allard S, Florence E, Demeester R, Callens S, Laga M. High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports. Sexual Health 2019;16(1):80 View
8. De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, Vuylsteke B, Crucitti T. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones inMycoplasma genitaliumin Belgium: results from samples collected between 2015 and 2018. Sexually Transmitted Infections 2021;97(4):297 View
9. Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, Kenyon C, Wouters K, Laga M. Daily and event‐driven pre‐exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. Journal of the International AIDS Society 2019;22(10) View
10. Bullinger J, Reyniers T, Vuylsteke B, Laga M, Nöstlinger C. Congruence between Hypothetical Willingness to Use Pre-Exposure Prophylaxis (PrEP) and Eligibility: An Online Survey among Belgian Men Having Sex with Men. International Journal of Environmental Research and Public Health 2019;16(22):4411 View
11. Kenyon C, Baetselier I, Wouters K. Screening for STIs in PrEP cohorts results in high levels of antimicrobial consumption. International Journal of STD & AIDS 2020;31(12):1215 View
12. Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, Smekens B, Buyze J, Vuylsteke B. Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project. JAIDS Journal of Acquired Immune Deficiency Syndromes 2018;79(2):186 View
13. Cordioli M, Gios L, Huber J, Sherriff N, Folch C, Alexiev I, Dias S, Nöstlinger C, Gama A, Naseva E, Valkovičová Staneková D, Marcus U, Schink S, Rosinska M, Blondeel K, Toskin I, Mirandola M. Estimating the percentage of European MSM eligible for PrEP: insights from a bio-behavioural survey in thirteen cities. Sexually Transmitted Infections 2021;97(7):534 View
14. Van Dijck C, Tsoumanis A, Rotsaert A, Vuylsteke B, Van den Bossche D, Paeleman E, De Baetselier I, Brosius I, Laumen J, Buyze J, Wouters K, Lynen L, Van Esbroeck M, Herssens N, Abdellati S, Declercq S, Reyniers T, Van Herrewege Y, Florence E, Kenyon C. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. The Lancet Infectious Diseases 2021;21(5):657 View
15. Reyniers T, Zimmermann H, Davidovich U, Vuylsteke B, Laga M, Hoornenborg E, Prins M, De Vries H, Nöstlinger C. The social meanings of PrEP use – A mixed‐method study of PrEP use disclosure in Antwerp and Amsterdam. Sociology of Health & Illness 2021;43(6):1311 View
16. Kenyon C. Dual Azithromycin/Ceftriaxone Therapy for Gonorrhea in PrEP Cohorts Results in Levels of Macrolide Consumption That Exceed Resistance Thresholds by up to 7-Fold. The Journal of Infectious Diseases 2021;224(9):1623 View
17. Jongen V, Reyniers T, Ypma Z, Schim van der Loeff M, Davidovich U, Zimmermann H, Coyer L, van den Elshout M, de Vries H, Wouters K, Smekens T, Vuylsteke B, Prins M, Laga M, Hoornenborg E. Choosing event‐driven and daily HIV pre‐exposure prophylaxis – data from two European PrEP demonstration projects among men who have sex with men. Journal of the International AIDS Society 2021;24(8) View
18. Vuylsteke B, Reyniers T, Nöstlinger C, Smekens T, Kenyon C, Laga M. Can We Predict Incorrect PrEP Use in High HIV Risk Situations Among Men Who Have Sex With Men? An Analysis of Be-PrEP-ared, the Belgian PrEP Demonstration Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021;88(1):36 View
19. De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, Crucitti T. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. International Journal of STD & AIDS 2022;33(4):385 View
20. Kenyon C, De Baetselier I, Vanbaelen T, Buyze J, Florence E. The Population-Level Effect of Screening for Mycoplasma genitalium on Antimicrobial Resistance: A Quasi-Experimental Study. Sexually Transmitted Diseases 2021;48(9):629 View
21. Demart S. « On n’arrive pas à les toucher » : la PrEP, les migrant.e.s africain.e.s et la production de l’ignorance. Global Health Promotion 2022;29(3):151 View
22. De Baetselier I, Reyniers T, Platteau T, Wouters K, Nöstlinger C, Cuylaerts V, Buyze J, Laga M, Kenyon C, Crucitti T, Vuylsteke B. Recurrent Sexually Transmitted Infections Among a Cohort of Men Who Have Sex With Men Using Preexposure Prophylaxis in Belgium Are Highly Associated With Sexualized Drug Use. Sexually Transmitted Diseases 2021;48(10):726 View
23. De Baetselier I, Smet H, Abdellati S, De Deken B, Cuylaerts V, Reyniers T, Vuylsteke B, Crucitti T. Evaluation of the ‘Colli-Pee’, a first-void urine collection device for self-sampling at home for the detection of sexually transmitted infections, versus a routine clinic-based urine collection in a one-to-one comparison study design: efficacy and acceptability among MSM in Belgium. BMJ Open 2019;9(4):e028145 View
24. MacDonald J, Estcourt C, Flowers P, Nandwani R, Frankis J, Young I, Clutterbuck D, Dalrymple J, McDaid L, Steedman N, Saunders J, Demant D. Improving HIV pre-exposure prophylaxis (PrEP) adherence and retention in care: Process evaluation and recommendation development from a nationally implemented PrEP programme. PLOS ONE 2023;18(10):e0292289 View
25. Van Oost N, Van Raemdonck A, Schoenmakers B. Piloting the Impact of an e-Learning on Knowledge About HIV Prevention and Prophylaxis Among General Practitioners in Belgium. Journal of Medical Education and Curricular Development 2024;11 View